Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Aug 31, 2012

NEW YORK (GenomeWeb News) – Roche said this week that it has appointed Daniel O'Day, current COO of Roche Diagnostics, to be COO of Roche Pharma, taking over for Pascal Soriot, who has left the firm to become CEO of AstraZeneca. Roland Diggelmann will succeed O'Day as COO of Roche Diagnostics.

Diggelmann, who currently is head of the Asia-Pacific region within Roche Diagnostics, also has been appointed to be a new member of the executive committee by the board of directors. Diggelmann joined Roche in 2008, and he formerly worked in sales and marketing in Europe and the Asia-Pacific region with Sulzer Medica/Centerpulse and Zimmer.

O’Day, has held various positions at Roche since he started with Roche Pharmaceuticals in 1987, including serving as head of molecular diagnostics.


Real Time Genomics has tapped Francisco De La Vega to head the firm's commercial operations as VP of genome science.

De La Vega spent 13 years at Applied Biosystems, where he was a scientific fellow and VP of next-generation sequencing applications. He also was a visiting professor at the Department of Genetics of the Stanford School of Medicine, where he conducted research in population genetics, and he was a member of the steering committee of the 1000 Genomes Project Consortium.


Baylor College of Medicine Associate Professor Amy McGuire has been named director of BCM's Center for Medical Ethics and Health Policy.

McGuire, an expert in ethical and policy issues related to genomics who has been at BCM since 2004, takes over the director role from Baruch Brody, who was director of the center for 30 years. She currently is investigating genomic data sharing, issues surrounding the return of genomic data results, microbiome ethics, and policy issues related to the clinical integration of genomics.


Chembio this week named Michael Steele vice president of sales, marketing, and business development.

Steele was previously employed by Chembio as a consultant. Before that he was vice president of business development at Seracare Life Sciences, as well as director and managing director at Serologicals before it was acquired by Millipore.


Molecular diagnostics firm NexDx has named Zachary Hornby VP of corporate development and Kurt Krummel director of molecular diagnostics and assay development.

Krummel joins NexDx from Celula, where he was associate director of biology, and he was a postdoctoral researcher at The Salk Institute, where his work focused on studying tumor suppression genetics.

Hornby previously was senior director of business development at Fate Therapeutics, and he held various positions at Halozyme Therapeutics, Neurocrine Biosciences and TKT, now Shire Human Genetic Therapies.


Matthias Mann next week will receive the 2012 Körber European Science Prize, which includes a €750,000 ($945,000) award, from the Körber Foundation. Mann, who is director of the Max Planck Institute of Bioechemistry, was awarded the prize for his research in proteomics and development of innovations in mass spectrometry.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.